In glomerulonephritis

Nassberger, L. et al., Antibodies to neutrophil granulocyte myeloperoxidase and elastase Autoimmune responses in glomerulonephritis due to hydralazine treatment, J. Intern. Med., 229, 261, 1991. 

Floege, J., Ostendorf, T., Janssen, U., Burg, M., Radeke, H.H., Vargeese, C. et al. (1999) Novel approach to specific growth factor inhibition in vivo—Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers. Am.J. Pathol., 154, 169-179. 

Cl. Couser, W. G., Pathogenesis of glomerular damage in glomerulonephritis. Nephrol. Dial. Transplant. 13, S10-S15 (1998). 

Okuda et al. (1990) provided evidence of an elevated expression of transforming growth factor-, proteoglycans and fibronectin in glomerulonephritis induced in rats by injection of anti-thymocyte serum. 

Holdsworth SR, Kitching AR, Tipping PG Thl and Th2T helper cell subsets affect patternsofinjury and outcomes in glomerulonephritis. Kidney Int 1999 55 1198-216. 

Other manifestations of mTOR inhibitor renal effects are delayed recovery from ischemic renal injury. In rats not on cyclosporine, siroiimus impairs recovery from acute renal ischemia [785]. Human series describe delayed recovery from post-transplant ischemic injury, and worsening function in glomerulonephritis in the presence of siroiimus [786-787]. Few studies have tested TAC and everoiimus for similar changes [788]. 

Ravnskov U. Hydrocarbons may worsen renal function in glomerulonephritis A meta-analysis ofthe case-control studies. Am J Ind Med 2000 37 599-506. 

---